IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma
This study has been completed.
Sponsor:
National Institutes of Health Clinical Center (CC)
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00018954
First received: July 11, 2001
Last updated: February 16, 2012
Last verified: February 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of two treatment regimens for patients in developing countries with diffuse non-Hodgkin's lymphoma and acute lymphoblastic leukemia.
| Condition | Intervention | Phase |
|---|---|---|
| Leukemia Lymphoma | Drug: asparaginase Drug: cyclophosphamide Drug: cytarabine Drug: daunorubicin hydrochloride Drug: doxorubicin hydrochloride Drug: etoposide Drug: ifosfamide Drug: mercaptopurine Drug: methotrexate Drug: prednisone Drug: vincristine sulfate Procedure: conventional surgery Radiation: radiation therapy | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Treatment |
| Official Title: | PILOT MULTINATIONAL PROTOCOLS IN ACUTE LYMPHOBLASTIC LEUKEMIA AND DIFFUSE NON-HODGKIN'S LYMPHOMA |
Resource links provided by NLM:
Genetic and Rare Diseases Information Center resources:
Acute Lymphoblastic Leukemia
B-cell Lymphoma
Diffuse Large B-Cell Lymphoma
Lymphosarcoma
Chronic Lymphocytic Leukemia
Leukemia, B-cell, Chronic
Mantle Cell Lymphoma
Lymphoma, Large-cell
Childhood Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma
Burkitt Lymphoma
Marginal Zone Lymphoma
Plasmablastic Lymphoma
Lymphoma, Large-cell, Immunoblastic
U.S. FDA Resources
Further study details as provided by National Institutes of Health Clinical Center (CC):
Show Detailed Description
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS:
-
Newly diagnosed acute lymphoblastic leukemia (ALL)
-
Lymphoblasts comprising more than 25% of nucleated cells on bone marrow aspirate
- Associated with an appropriate clinical syndrome
-
- OR
- Histologically proven newly diagnosed diffuse non-Hodgkin's lymphoma (NHL)
- Immunologic and/or cytochemical confirmation of diagnosis preferred
PATIENT CHARACTERISTICS:
Age:
-
ALL:
- Under 25
-
NHL:
- Not specified
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- No prior therapy for ALL or NHL
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00018954
Please refer to this study by its ClinicalTrials.gov identifier: NCT00018954
Locations
| United States, Maryland | |
| Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support | |
| Bethesda, Maryland, United States, 20892-1182 | |
| Egypt | |
| National Cancer Institute of Egypt | |
| Cairo, Egypt | |
| India | |
| Kidwai Memorial Institute of Oncology | |
| Bangalore, India, 560029 | |
| Cancer Institute (W.I.A.) | |
| Madras, India, 600020 | |
| Tata Memorial Centre | |
| Mumbai, India, 400012 | |
Sponsors and Collaborators
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Investigators
| Study Chair: | Ian Trevor Magrath, MD, FRCP, FRCPath | National Cancer Institute (NCI) |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00018954 History of Changes |
| Other Study ID Numbers: |
CDR0000077227 NCI-92-C-0030 NCI-T91-0259N OH92-C-0030 |
| Study First Received: | July 11, 2001 |
| Last Updated: | February 16, 2012 |
Keywords provided by National Institutes of Health Clinical Center (CC):
|
stage I childhood lymphoblastic lymphoma stage II childhood lymphoblastic lymphoma stage III childhood lymphoblastic lymphoma stage IV childhood lymphoblastic lymphoma untreated adult acute lymphoblastic leukemia untreated childhood acute lymphoblastic leukemia stage I adult diffuse small cleaved cell lymphoma stage I adult diffuse mixed cell lymphoma stage I adult diffuse large cell lymphoma stage I adult immunoblastic large cell lymphoma stage I adult lymphoblastic lymphoma stage I adult Burkitt lymphoma stage III adult diffuse small cleaved cell lymphoma stage III adult diffuse mixed cell lymphoma stage III adult diffuse large cell lymphoma |
stage III adult immunoblastic large cell lymphoma stage III adult lymphoblastic lymphoma stage III adult Burkitt lymphoma stage IV adult diffuse small cleaved cell lymphoma stage IV adult diffuse mixed cell lymphoma stage IV adult diffuse large cell lymphoma stage IV adult immunoblastic large cell lymphoma stage IV adult lymphoblastic lymphoma stage IV adult Burkitt lymphoma stage I childhood small noncleaved cell lymphoma stage I childhood large cell lymphoma stage II childhood small noncleaved cell lymphoma stage II childhood large cell lymphoma stage III childhood small noncleaved cell lymphoma stage III childhood large cell lymphoma |
Additional relevant MeSH terms:
|
Lymphoma Leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Lymphoid Lymphoma, Non-Hodgkin Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Methotrexate Cytarabine 6-Mercaptopurine Doxorubicin |
Etoposide Daunorubicin Cyclophosphamide Liposomal doxorubicin Prednisone Vincristine Asparaginase Ifosfamide Abortifacient Agents, Nonsteroidal Abortifacient Agents Reproductive Control Agents Physiological Effects of Drugs Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on July 11, 2017